The event will be chaired by Ashok Kumar, Secty. Dept. of Pharmaceuticals and co-chaired by Glenn Saldhana, Chairman, FICCI National Pharmaceuticals Committee & MD and CEO, Glenmark Pharmaceuticals. Organisers are the Government of India's new Department of Pharmaceuticals and UBM India Pvt. Ltd. Venue is the Mumbai Grand Hyatt.
Staged alongside the first two days of CPhI India, in the BioPh pavilion at the Bombay Exhibition Centre, Biosimilars India 2009 will cover a wide range of topics in 17 sessions across three half-day modules.
"India is now moving towards centrestage in world pharma, with its overall pharma market growing at better than 9% - and key segments much faster. CPhI and the co-located events are the natural meeting point that enables a high level of networking and business development across the academic, development, R&D, services and manufacturing communities", said CPhI India Event Director Annemieke Timmers.
"With the BioPh India and ICSE India launches and a strong conference programme adding to a high level of pre-registrations, all our indications are that this year in Mumbai will see our strongest Indian events so far", added ICSE, BioPh and P-MEC Event Director Haf Cennydd.
Key industry organisations supporting the exhibitions will include Pharmexcil - the Government of India's pharmaceutical export promotion council; the Indian Drug Manufacturers Association (IDMA); the Organisation of Pharmaceutical Producers of India (OPPI) and the Bulk Drug Manufacturers Association (India) (BDMA).
The events are jointly organised by U
|SOURCE CPhI India|
Copyright©2009 PR Newswire.
All rights reserved